|Bid||67.54 x 13000|
|Ask||68.21 x 12700|
|Day's Range||67.78 - 67.78|
|52 Week Range||54.08 - 72.61|
|Beta (3Y Monthly)||0.72|
|PE Ratio (TTM)||22.75|
|Forward Dividend & Yield||0.67 (0.94%)|
|1y Target Est||N/A|
On a per-share basis, the Deerfield, Illinois-based company said it had net income of 66 cents. Earnings, adjusted for non-recurring costs, came to 76 cents per share. The results beat Wall Street expectations. ...
Investment company Morgan Stanley Institutional Global Franchise Fund buys Baxter International Inc, Heineken NV during the 3-months ended 2018Q4, according to the most recent filings of the investment ...
Baxter (NYSE:BAX) remains the firm's largest position and Third Point Partner and Head of Equities Munib Islam serves on the Board of Directors. In past quarterly letters, we detailed our initial investment thesis and highlighted the extraordinary transformation that CEO Joe Almeida has overseen at the company since joining at the end of 2015. Warning! GuruFocus has detected 6 Warning Signs with BAX.
Baxter International Inc said the U.S. Justice Department has closed an antitrust probe examining possible communication among producers of intravenous saline solutions during supply shortages that created higher prices. Baxter, which received a grand jury subpoena in 2017 as part of the investigation, said in a filing with the U.S. Securities and Exchange Commission on Thursday that the department informed it on Nov. 30 of its decision to end the probe. Other companies that in April 2017 disclosed receiving subpoenas as part of the investigation included Pfizer Inc and ICU Medical Inc, which earlier that year had acquired Pfizer's global infusion therapy business.
Baxter International Inc operates in the healthcare industry. The dividend yield of Baxter International Inc stocks is 0.98%. Baxter International Inc had annual average EBITDA growth of 0.40% over the past ten years.
A new venture to supply generic medicines says it will start with a blood-pressure drug that has been hard to get. ProvideGx, the new generic-drug venture, will begin supplying metoprolol in the middle of this month, according to executives at Premier Inc., which unveiled the subsidiary last month. Neither Premier nor Baxter would say how much their metoprolol would be priced, saying they don’t want to disclose the price to competitors.
On a per-share basis, the Deerfield, Illinois-based company said it had profit of 65 cents. Earnings, adjusted for non-recurring costs and to account for discontinued operations, came to 78 cents per share. ...
Shares of Baxter International Inc (NYSE: BAX ) are trading at a valuation that implies low growth, but Morgan Stanley sees three catalysts ahead that will likely result in top-and-bottom line acceleration ...
The Swiss firm says Abbott Labs, Boston Scientific, Medtronic, Stryker, Baxter International and Edwards Lifesciences will outperform, while Zimmer Biomet will underperform
Daniel Loeb (Trades, Portfolio), whose fund is posting negative returns this year, reported on Wednesday that he unloaded a portion of one of his highly profitable bets, health care company Baxter International (BAX). Warning! GuruFocus has detected 1 Warning Sign with GOOG. The sale resulted from the "portfolio concentration level" it had reached in the portfolio of his hedge fund, Third Point.
In the daily bar chart of BAX, below, we can see a sharp decline in October that included a gap to the downside earlier this week. The slopes of both of these lagging indicators are negative or bearish. The daily On-Balance-Volume (OBV) line showed a positive trend until late September.
Baxter (BAX) delivered earnings and revenue surprises of 8.11% and -0.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Deerfield, Illinois-based company said it had net income of $1. Earnings, adjusted for non-recurring gains, were 80 cents per share. The results surpassed Wall Street expectations. ...
Long-term growth prospects of the Medical Products industry looks promising despite certain short-term political conundrums.